Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.
InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.
InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.
Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.
In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.
InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.
For more detailed information and the latest updates, visit InMode's official website.
InMode Ltd. (Nasdaq: INMD) announced that its leadership team, including Moshe Mizrahy (CEO), Yair Malca (CFO), and Spero Theodorou (CMO), will present at the 25th Annual Needham Growth Conference on Jan. 12, 2023. The event, moderated by Mike Matson, starts at 10:15 am Eastern Time and will be accessible via webcast on InMode's Investor Relations website. Additionally, InMode will conduct in-person meetings on Jan. 11 and virtual meetings on Jan. 12.
InMode Ltd. (Nasdaq: INMD), a global leader in medical technologies, announced participation in three major investor conferences in November and December 2022. The events include:
- Jefferies London Healthcare Conference: Presentation on November 15 at 10:20 a.m. GMT
- Canaccord Genuity MTDF Conference: Presentation on November 17 at 1:00 p.m. ET
- Cantor Medical & Aesthetic Dermatology Conference: Panel on December 8 at 1:45 p.m. ET
Live webcasts will be available for each presentation. For more details, visit InMode's website.
InMode Ltd. (Nasdaq: INMD) reported a record-breaking revenue of $121.2 million for Q3 2022, marking a 29% increase compared to Q3 2021. The company achieved a GAAP net income of $48.8 million or $0.58 per diluted share, up from $44.7 million or $0.52 in the previous year. Non-GAAP net income reached $56.6 million with a non-GAAP EPS of $0.66. Significant growth was seen in consumables and services, increasing 53% year-over-year to $13.9 million. Management also increased revenue targets for the EmpowerRF platform and plans global expansion.
InMode Ltd. (Nasdaq: INMD) anticipates record third-quarter revenue between $120.5 million and $120.9 million, alongside a projected non-GAAP gross margin of 84% to 85% and earnings per diluted share ranging from $0.64 to $0.65. The company has also raised its full-year 2022 revenue guidance to between $445 million and $450 million. A conference call to discuss these results is scheduled for October 27, 2022, at 8:30 a.m. ET.
On September 29, 2022, InMode Ltd. (Nasdaq: INMD) announced actress Eva Longoria as its Global Brand Ambassador. Longoria, known for her work on Desperate Housewives and her philanthropic efforts, will promote InMode's innovative medical technologies. She has personally utilized InMode’s EvolveX Transform and Morpheus8 Body treatments to address post-pregnancy body changes, emphasizing their effectiveness. InMode develops and markets cutting-edge devices leveraging radiofrequency technology across multiple medical fields, striving to enhance surgical procedures and existing treatments.
InMode Ltd. (Nasdaq: INMD) announced that CFO Yair Malca will present at the Baird 2022 Global Healthcare Conference on Sept. 13, 2022, at 1:25 pm Eastern Time at the InterContinental New York Barclay hotel. The presentation will be webcast on InMode's Investor Relations website. Malca will also hold one-on-one investor meetings on Sept. 13 and Sept. 14. InMode specializes in innovative medical technologies, focusing on minimally invasive RF technologies applicable in various medical fields.
InMode Ltd. (NASDAQ: INMD), a leader in innovative medical technologies, announced participation in the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16, 2022. Senior management, including Chairman and CEO Moshe Mizrahy and CFO Yair Malca, will engage in one-on-one meetings with investors that day. Interested parties can schedule meetings via their Needham representatives. InMode develops cutting-edge devices using radiofrequency technology for various medical fields, emphasizing minimally invasive surgical solutions.
InMode Ltd. (Nasdaq: INMD) reported record revenues of $113.5 million for Q2 2022, marking a 30% increase year-over-year. The company's GAAP net income rose to $44.0 million, with earnings per diluted share at $0.52. Non-GAAP net income reached $50.4 million, translating to $0.59 per diluted share. The company expects 2022 revenues of $425 million to $435 million and a non-GAAP gross margin between 83% and 85%. InMode also received Health Canada's endorsement for its EmpowerRF platform.
InMode Ltd. (NASDAQ: INMD) announced that CFO Yair Malca will present at the Canaccord 42nd Annual Growth Conference on August 11, 2022, at 3:30 PM ET, in Boston. The presentation will be available via webcast on the company's Investor Relations website. Malca is also scheduled for one-on-one meetings with investors on August 10 and August 11. InMode specializes in innovative medical technologies, focusing on minimally invasive RF procedures in various medical fields.
InMode Ltd. (INMD) announced expectations for record financial results in Q2 2022, forecasting revenue between $113.0 million to $113.3 million. The company anticipates a non-GAAP earnings per diluted share of $0.57 to $0.58. Additionally, InMode raised its full-year revenue guidance to a range of $425 million to $435 million, up from a previous range of $415 million to $425 million. The company attributes this growth to strong demand for its medical technologies in aesthetic surgery.
FAQ
What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?
What is the market cap of InMode Ltd. Ordinary Shares (INMD)?
What products does InMode Ltd. offer?
What are InMode's core business categories?
Which markets does InMode serve?
How did InMode perform in Q3 2023?
What are some of InMode's flagship products?
What recent legal actions has InMode taken?
What new platforms has InMode recently announced?
Who is the new Chairman of InMode's Board?
What partnership has InMode recently entered into?
Where can I find more information about InMode?
